Immunitybio Inc (IBRX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché IBRX Giù? Forum Previsione

Perché le azioni Immunitybio Inc (IBRX) sono in ribasso?

Abbiamo notato un calo di 5.34% nelle azioni di Immunitybio Inc (IBRX) durante la sessione di negoziazione di 2024-09-30. Sebbene ciò possa essere attribuito alla normale volatilità o a vari fattori interni ed esterni, tieni presente che stiamo monitorando attivamente la situazione e forniremo aggiornamenti tempestivi il prima possibile!

2023-05-22:

IBRX's stock fell 6.06% related to the investigation claims against the company. The investigation focuses on whether IBRX issued false and/or misleading statements and/or failed to disclose information pertinent to investors. ImmunityBio announced on May 11, 2023, that it "has received a complete response letter from the U.S. Food and Drug Administration ("FDA") on May 9, 2023 regarding its Biologics License Application ("BLA") for its product candidate, Anktiva™ (N-803) in combination with Bacillus Calmette-Guérin ("BCG"). The letter indicates that the FDA has determined that it cannot approve the BLA in its present form, and the FDA has made recommendations to address the issues raised."

https://www.accesswire.com/viewarticle.aspx?id=756192&lang=en

2023-05-11:

ImmunityBio’s stock price has fallen after receiving a response from the U.S. Food and Drug Administration (FDA). The FDA has rejected ImmunityBio’s application for Anktiva as a bladder cancer treatment.

https://investorplace.com/2023/05/why-is-immunitybio-ibrx-stock-down-54-today/